Company newsCompany release
Viking Therapeutics VKTX
Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026
In an exploratory analysis of its Phase 2 VENTURE trial, 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo.
GetSignal
Viking Therapeutics said on November 15, 2026 that new clinical data from its VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek, which runs from November 14 to 17, 2026, in Washington, D.C.
The company presented results from an exploratory analysis of its Phase 2 VENTURE trial, in which participants received VK2735 as a weekly subcutaneous injection. The analysis covers changes in obesity severity and cardiometabolic measures after 13 weeks. It found that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one body mass index category, compared with 15% of placebo participants. None of the VK2735-treated participants had an increase in BMI category.
Among VK2735-treated participants, those who improved by at least one BMI category showed greater reductions in waist circumference, fasting insulin and glucose, blood pressure, total cholesterol, triglycerides and LDL cholesterol than those whose BMI category did not change.
Brian Lian, Ph.D., chief executive officer of Viking Therapeutics, said the analysis supports the company's belief that weight loss from VK2735 treatment may improve overall cardiometabolic health.
A second poster presented baseline characteristics of participants in the ongoing Phase 3 VANQUISH-2 study, which evaluates subcutaneous VK2735 in adults with overweight or obesity and type 2 diabetes. Jamy Ard, MD, presented it. Viking Therapeutics said the VANQUISH studies are expected to be completed in 2027.
Key facts
- Participants on weekly subcutaneous VK2735 with at least one BMI category improvement
- 74%
- Placebo participants with at least one BMI category improvement
- 15%
- VK2735-treated participants with an increase in BMI category
- None
- ObesityWeek dates
- November 14 to 17, 2026
- VANQUISH studies expected to be completed
- 2027
Source: The company's release on PR Newswire, November 15, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Viking Therapeutics first, then the newest- Viking Therapeutics to present two VK2735 posters at ObesityWeek 2026
VKTX · Viking Therapeutics · Company release · Nov 9, 2026
- Canadian Natural Resources agrees to acquire Advantage Energy
CNQ · Canadian Natural Resources · Company release · Nov 16, 2026
- Rio Tinto, BCL and ABG agree to establish fund for Panguna mine legacy impacts
RIO · Rio Tinto Group · Company release · Nov 16, 2026
- CVS Health study finds GLP-1 medical savings do not fully offset pharmacy spending at current prices
CVS · CVS Health · Company release · Nov 15, 2026
- Rocket Lab reaches 100 Electron launches
RKLB · Rocket Lab · Company release · Nov 14, 2026
